Skip to main content

Table 1 Patient demographics of AEs related to T-VEC in the FAERS database

From: Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)

Characteristic

Case N (%)

Total

1138

Sex

 Female

373(32.8%)

 Male

401(35.2%)

 Unknown

364(32.0%)

Reporting country

 USA

894(78.6%)

 Rest of the world

243(21.3%)

 Unknown

1(0.1%)

Reporting year

 2023 quarter 1 to 2023 quarter 3

71(6.2%)

 2022

116(10.2%)

 2021

115(10.1%)

 2020

131(11.5%)

 2019

151(13.3%)

 2018

183(16.1%)

 2017

194(17.0%)

 2016

176(15.5%)

 2015 and before

1(0.1%)

Age at onset

  < 18 years

3(0.3%)

 18 ~ 44 years

54(4.5%)

 45 ~ 59 years

167(14.7%)

  ≥ 60 years

391(34.4%)

 Unknown

523(46.0%)

Outcome

 Death

116(10.2%)

 Life-threatening

23(2.0%)

 Hospitalization

234(20.6%)

 Disability

11(1.0%)

 Other serious events

437(38.4%)

 Unknown

317(27.9%)